Welltower Inc. (WELL) — Q2 2026 Earnings Preview

1. Earnings Preview

Key Takeaway: The setup favors another beat — consensus for Q2 Normalized FFO/share sits at ~$1.55, a bar management has consistently cleared by a wide margin, and the summer leasing season (management's own flagged wildcard) appears to be tracking well based on peer commentary; the single biggest swing factor is whether SHO same-store NOI growth can sustain the 20%+ pace or begins to moderate toward the guided 16.5–21.5% full-year range.

Heading into Q2 2026 results, the bar for Welltower looks achievable but not trivial: consensus Normalized FFO/share of ~$1.55 implies roughly 21% year-over-year growth, consistent with the trajectory management guided to after raising full-year 2026 FFO guidance by $0.11 at the midpoint to $6.28/share following Q1. Management's tone on the Q1 call was unambiguously bullish — CEO Shankh Mitra described the business as "firing on all cylinders" and stated the best years are "squarely in front of us," while COO John Burkart highlighted the 14th consecutive quarter of 20%+ SHO same-store NOI growth. Estimate revisions have been broadly stable since the Q1 print (consensus FFO for Q2 moved from ~$1.55 to ~$1.55, essentially flat), suggesting the street has largely digested the raised guidance without adding incremental cushion — a neutral-to-slightly-positive setup. The stock has surged ~18% since the April 28 earnings date (from $214 to $252), trading at a NTM EV/EBITDA of ~32x, a premium that prices in continued outperformance and leaves limited room for a miss. The key wildcard is the summer leasing season: management explicitly flagged this on the Q1 call as the critical variable for the year, and Q2 is the peak occupancy-building quarter — a strong sequential occupancy gain above the guided 350 bps YoY would be the most positive surprise, while any softening in RevPOR growth or labor cost re-acceleration would be the primary downside risk.

Bar: Consensus SHO same-store NOI growth of ~20.7% for Q2 is a high bar in absolute terms but sits within the guided 16.5–21.5% full-year range; given Q1 came in at 22.1% (above the top of the range), the street is effectively pricing in modest deceleration — achievable but not a layup.

Guidance/Tone: Management raised full-year FFO guidance by $0.11 at the midpoint after Q1 and expressed high conviction in multi-year occupancy and pricing runway, with total SHO portfolio occupancy at 87% leaving ~half of same-store assets below 90%. No post-Q1 guidance revision has been issued; the July 13 C$1.15B Canadian dollar notes offering signals continued aggressive capital deployment rather than any defensive posture.

Estimate Trajectory: Revisions have been broadly flat since the Q1 print — Q2 FFO consensus moved from $1.554 (as of May 5) to $1.547 currently, a negligible -0.5% drift. Full-year 2026 FFO consensus is essentially unchanged at $6.298 vs. $6.299 at the post-Q1 baseline. The flat trajectory reflects a street that believes guidance is credible but is not adding incremental upside — creating a modest beat cushion if operational momentum continues.

Stock Setup: WELL has outperformed XLRE by ~15 percentage points since Q1 earnings, with the stock up ~18% vs. XLRE flat-to-slightly-up. At 32x NTM EV/EBITDA (vs. ~28x six months ago), the multiple has expanded ~18% over six months, meaning the majority of the price gain has been multiple-driven rather than estimate-driven. This is a stretched setup — a beat is likely needed just to hold the current level.

Wildcard: The summer leasing season occupancy read — management explicitly called this out as the key variable on the Q1 call. A sequential occupancy gain materially above seasonal norms (WELL has been defying seasonality) would validate the multi-year growth thesis and likely drive further multiple expansion; any miss on occupancy or a re-acceleration in labor costs would be the primary catalyst for a pullback from elevated levels.

2. KPIs & Consensus Expectations

Key Takeaway: Consensus sets a high but achievable bar — SHO same-store NOI growth of ~20.7% and occupancy of ~90.3% both imply modest deceleration from Q1's record 22.1% and 89.0%, respectively; SHO same-store NOI growth is the bigger swing factor given its outsized contribution (~75% of total portfolio NOI) and the widest range in the guidance band (16.5–21.5%).

Table 1 — Current Quarter Snapshot (Q2 2026 Key KPIs)

Sources: Visible Alpha Consensus and Actuals Data (Normalized FFO per share-Diluted, Same store NOI growth YoY – Seniors Housing Operating, Same store Occupancy – Seniors Housing Operating, Same store RevPOR YoY – Seniors Housing Operating, Same store expense growth YoY – Seniors Housing Operating). Full-year 2026 guidance from Welltower Q1 2026 Earnings Call (April 29, 2026).

Table 2 — Beat/Miss History (Last 8 Quarters, Top 2 KPIs)

KPI 1: Normalized FFO per Share — Diluted ($)

KPI 2: SHO Same-Store NOI Growth YoY (%)

Pattern: Normalized FFO/share has beaten consensus in every quarter with available data (7 for 7), with surprise magnitudes ranging from +0.4% to +6.5% — a remarkably consistent beat cadence. SHO same-store NOI growth is more volatile: 5 beats, 2 misses, 1 in-line over 8 quarters, with misses concentrated in Q3–Q4 2025 when the street set an overly aggressive bar; Q1 2026's +4.0 pp beat was the largest in recent history, resetting expectations higher.

Source: Visible Alpha Consensus and Actuals Data (Normalized FFO per share-Diluted; Same store NOI growth – YoY – Seniors Housing Operating).

Note on Disclosure vs. Action Dates: The Q1 2026 earnings release was filed as an 8-K on April 28, 2026 (disclosure date); the earnings conference call occurred April 29, 2026 (action date for guidance commentary). The C$1.15B Canadian dollar notes offering: Underwriting Agreement signed July 6, 2026 (corporate action date); notes issued July 13, 2026 (corporate action/settlement date); 8-K filed July 13, 2026 (disclosure date). No formal guidance revision was issued in connection with the notes offering.

Source: Welltower Q1 2026 Earnings Call transcript (April 29, 2026); Welltower 8-K filed July 13, 2026 (C$1.15B notes offering); Visible Alpha Consensus and Actuals Data.

4. Guidance vs. Estimate Revision Tracker

Key Takeaway: Estimates have been essentially flat since the Q1 print — Q2 FFO consensus drifted just −0.5% and FY 2026 FFO consensus is unchanged — suggesting the street fully absorbed the raised guidance without adding incremental upside. The gap between consensus and guidance midpoint is narrow and represents a modest cushion rather than a risk.

Commentary: The flat estimate trajectory since Q1 is a healthy setup — the street has not over-extrapolated the Q1 beat into Q2, leaving room for a positive surprise if the summer leasing season delivers. The one area of tension is SHO occupancy: Q2 consensus of ~90.3% implies only ~190 bps of YoY gain, well below the 350 bps FY midpoint, which means H2 must carry the bulk of the occupancy build. If Q2 occupancy comes in above 90.3%, it would de-risk the FY target and likely drive upward revisions to the full-year SHO NOI growth estimate (currently near the top of the guided range).

Source: Visible Alpha Consensus and Actuals Data (as-of date May 5, 2026 for post-Q1 baseline; latest as of July 26, 2026). Guidance from Welltower Q1 2026 Earnings Call (April 29, 2026).

5. Stock Performance

Key Takeaway: WELL has surged ~17.7% since Q1 earnings (April 28 close: $214.23 → July 24 close: $252.11), dramatically outperforming XLRE (+4.7%) and SPY (+3.8%); the outperformance is predominantly multiple-driven (NTM EV/EBITDA expanded ~18% over 6 months) rather than estimate-driven, reflecting sentiment re-rating toward the Welltower 3.0 transformation thesis.

Since Q1 earnings (April 28, 2026 close of $214.23), WELL has gained $37.88/share (+17.7%) to $252.11 as of July 24, 2026. Over the same period, XLRE gained approximately +4.7% (from $43.91 to $45.96) and SPY gained approximately +3.8% (from $711.69 to $738.97), implying WELL outperformed XLRE by ~13 percentage points and SPY by ~14 percentage points. The stock experienced a brief pullback in late May/early June (trough of ~$195 on June 2), likely reflecting broader REIT sector pressure and macro rate concerns, before recovering sharply through July on continued senior housing sector momentum and the C$1.15B notes offering signaling aggressive capital deployment. The NTM EV/EBITDA multiple has expanded from ~27.3x six months ago to ~32.2x today, with multiple expansion accounting for the majority of the 12-month price gain of +56%. This elevated multiple leaves the stock vulnerable to any operational disappointment.

Indexed Performance Table (Base = 100 at April 28, 2026 close):

Valuation Context: NTM EV/EBITDA of 32.2x (latest) vs. 27.3x six months ago (+17.9% multiple expansion) and 28.1x twelve months ago (+14.7% expansion). Over the trailing 12 months, price is up +56.0% while NTM EV/EBITDA expanded +14.7%, implying the remainder of the gain was driven by EBITDA estimate growth. The 1-month price gain of +13.9% was almost entirely multiple-driven (+10.8% multiple expansion). At 32x, WELL trades at a significant premium to the REIT sector and to its own history, pricing in sustained execution of the Welltower 3.0 transformation.

Sector ETF: XLRE (Real Estate Select Sector SPDR ETF) is used as the sector benchmark. XLRE is a broad real estate ETF covering diversified REITs, industrial, residential, and healthcare REITs — appropriate as a sector-level benchmark, though WELL's senior housing focus means it will naturally diverge from XLRE during periods of sector rotation within real estate.

Source: Stock Price Data (Yahoo Finance); Stock Performance Decomposition (NTM EV/EBITDA multiples).

6. Peer Commentary: Current-Quarter Read-Throughs

Key Takeaway: Eligible peer commentary from the last 60 days is uniformly positive for WELL's Q2 setup — Sabra's July 21 business update explicitly confirms low-to-mid-teens same-store managed senior housing NOI growth for full-year 2026, and AHR's June 2 REITweek commentary describes a multi-year demand/supply setup with "very nice" same-store NOI growth expected in both 2026 and 2027. Both reads support the bull case for WELL's SHO segment.

Eligibility Note: Only commentary explicitly about Q2 2026 operating conditions, full-year 2026 outlook, or forward-looking statements made after Q1 2026 earnings (i.e., after April 28, 2026) is included below. Commentary about Q1 2026 results (prior-quarter results) is excluded. The Ventas (VTR) 8-K filed June 15, 2026 (General Counsel resignation) contains no Q2 or FY 2026 operating commentary and is excluded. The NHI 8-K filed July 1, 2026 (NHC asset sale closing) relates to a skilled nursing disposition with no SHO read-through and is excluded. The AHR 8-K filed June 18, 2026 (Q2 distribution declaration) contains no operating commentary and is excluded.

Sabra Health Care REIT (SBRA) — Business Update, July 21, 2026

Disclosure Date: July 21, 2026 (8-K filed; business update press release as Exhibit 99.1). Corporate Action Dates: RCA mortgage repayment closed June 30, 2026 (Q2 event); Avamere re-tenanting LOIs signed prior to July 21 (H2 2026 transition expected); smaller portfolio initiatives mostly closed as of July 21.

Relevance to WELL: Sabra raised its full-year 2026 Normalized FFO guidance to $1.53–$1.55/share (midpoint +7% vs. 2025) and Normalized AFFO to $1.59–$1.61/share (midpoint +8% vs. 2025), incorporating year-to-date operational performance and transaction activity. Critically for WELL, Sabra's guidance explicitly assumes "average full-year Cash NOI growth for the same-store Senior Housing — Managed portfolio in the low-to-mid teens." This is a direct read-through for the broader managed senior housing operating environment and supports WELL's own SHO same-store NOI growth guidance of 16.5–21.5% (WELL's portfolio is higher quality and more operationally advanced, so WELL's growth rate running above Sabra's is consistent with the premium positioning). Sabra also noted its strategic focus on "increasing our managed senior housing concentration," underscoring sector-wide conviction in the SHO growth thesis.

• Managed SHO same-store NOI growth: Low-to-mid teens for full-year 2026 — positive read-through for WELL's 16.5–21.5% guided range.
• RCA mortgage repayment (closed June 30, 2026): Reduced behavioral health concentration from 13% to 9% of Annualized Cash NOI; Net Debt/EBITDA improved from 5.0x to 4.8x pro forma. Signals active balance sheet management across the sector.
• Avamere re-tenanting: 26 properties transitioning to Cascadia Healthcare and an existing tenant; combined annualized cash rent expected at $53M (vs. $41M from Avamere), a ~30% increase. Demonstrates operator transition execution capability and improving rent coverage in the SNF/SHO space.
• Guidance raise: Normalized FFO raised to $1.53–$1.55 (midpoint +7% YoY); Normalized AFFO to $1.59–$1.61 (midpoint +8% YoY). Reflects strong year-to-date operational performance — a positive sector signal.

American Healthcare REIT (AHR) — Nareit REITweek Investor Conference, June 2, 2026

Disclosure Date: June 2, 2026 (conference call transcript). This is a post-Q1 forward-looking conference presentation explicitly addressing Q2 2026 and full-year 2026/2027 outlook.

Relevance to WELL: AHR management provided extensive forward-looking commentary on the senior housing operating environment at REITweek, with several direct read-throughs for WELL:

• Sector demand/supply setup: AHR CEO described a "veritable demographic tsunami driving insatiable demand" meeting "very low, radically low and muted supply," creating a "multi-year setup for continued outsized growth." This macro framing directly supports WELL's thesis that the current SHO growth cycle has years of runway remaining.
• SHO same-store NOI growth outlook: AHR explicitly guided to "very nice same-store NOI growth in 2026 and very nice same-store NOI growth in 2027" for its Shop portfolio — a forward-looking statement about the current reporting period and beyond. This is a direct positive read-through for WELL's SHO segment.
• Revenue management innovation: AHR is test-piloting dynamic pricing/revenue management with two Shop operators, described as "going well." This signals the sector is finding new levers to drive RevPOR growth even as occupancy approaches stabilization — relevant for WELL's own RevPOR guidance of 5% growth.
• Occupancy and pricing power: Trilogy (AHR's largest operator) occupancy is "over 91% for the same-store portfolio" with NOI margins "now above 20%." AHR's pipeline has grown from $650M to "well over $1 billion" in awarded deals, with 100% of year-to-date closings representing expansion with existing operators — signaling strong operator confidence in the sector.
• Labor/expense trends: AHR highlighted Trilogy's purpose-built campus design as driving labor efficiency (optimal hallway layouts, shared staffing across care lines). No commentary suggesting labor cost re-acceleration — consistent with WELL's near-record-low ExpPOR growth in Q1.
• Skilled nursing rate growth: Trilogy achieved "over 5% rent growth in Medicare and over 8% in Medicare Advantage" in the prior year, well above the national average of 3%. This payer mix optimization is a positive read-through for WELL's triple-net and SHO segments with SNF exposure.
• Supply barriers: AHR noted the difficulty of developing new skilled nursing facilities profitably, reinforcing the structural supply constraint narrative that underpins WELL's multi-year growth thesis.

Bottom Line: AHR's REITweek commentary is the most substantive peer read-through available for WELL's Q2 setup. The combination of strong demand fundamentals, explicit NOI growth guidance for 2026 and 2027, revenue management innovation, and no labor cost concerns is uniformly positive for WELL's SHO segment heading into Q2 results.

Excluded Peer Disclosures (Non-Qualifying)

7. Material News & Developments

Key Takeaway: The most important post-Q1 development is the C$1.15B Canadian dollar notes offering (July 13), which signals continued aggressive capital deployment into the Canadian senior housing pipeline (Amica acquisition closed April 1) and confirms management's confidence in the growth outlook; no negative developments have emerged since Q1 earnings.

• July 13, 2026 — Welltower issues C$1.15B in Canadian Dollar Notes (8-K filed July 13, 2026; corporate action dates: Underwriting Agreement July 6, 2026; notes issued/settled July 13, 2026). Welltower OP LLC issued C$750M of 3.850% Notes due 2031 and C$400M of 4.150% Notes due 2033, fully guaranteed by Welltower Inc. on a senior unsecured basis. Proceeds designated for general corporate purposes including debt repayment and funding the investment pipeline in healthcare and seniors housing. Implication: The Canadian dollar denomination is a natural hedge for the Amica Senior Lifestyles acquisition (GTA and Vancouver markets, closed April 1, 2026). The offering signals management's confidence in the Canadian SHO pipeline and continued capital deployment at scale. Underwriters were RBC Dominion Securities, Scotia Capital, TD Securities, and BMO Nesbitt Burns — all major Canadian banks, consistent with the CAD-denominated strategy.
• April 29, 2026 — Q1 2026 Earnings: Record portfolio same-store NOI growth; FY 2026 FFO guidance raised $0.11 at midpoint to $6.28/share. 14th consecutive quarter of 20%+ SHO same-store NOI growth; net debt/EBITDA at 2.73x (record low); $10.5B of investments closed or under contract YTD; Amica acquisition ($3B+) closed April 1. Implication: Sets a high but achievable bar for Q2; the $4.2B of Q2 transactions already closed (as disclosed on the Q1 call) will contribute to Q2 investment income.
• April 29, 2026 — Welltower files to register 314,000+ shares for resale (8-K filed April 29, 2026). Routine registration of shares related to the Amica acquisition consideration. Implication: Administrative; no material impact on Q2 results.
• April 2026 — $700M unsecured bond maturity repaid using free cash flow (disclosed on Q1 call). Corporate action date: April 2026 (post-quarter-end). Implication: Reduces interest expense and demonstrates balance sheet strength; net debt/EBITDA expected to remain near 3x at year-end despite heavy investment activity.
• Q1 2026 (disclosed April 29) — Data science platform licensing partnerships with Public Storage and a leading global private equity real estate firm. First external monetization of Welltower's proprietary data science capital allocation platform. Implication: Capital-light revenue stream; management noted significant inbound interest from real estate companies, banks, and sovereign wealth funds. Potential to become a standalone business vertical. Not expected to be material to Q2 FFO but signals long-term optionality.
• Q1 2026 (disclosed April 29) — U.S. Seniors Housing Equity Fund fully committed ($2.5B). Final LP close occurred Q4 2025; entire fund capital now deployed. Implication: Validates the private funds management business as a new capital-light revenue vertical; fee income from the fund will contribute to Q2 and beyond.
• June 23, 2026 — Welltower announces Q2 2026 earnings release date (press release). Results to be released after NYSE close on July 27, 2026; conference call July 28, 2026 at 9:00 a.m. ET. Implication: Administrative; confirms timeline.
• July 21, 2026 — Sabra Health Care REIT (SBRA) business update: raises FY 2026 guidance; confirms low-to-mid-teens managed SHO same-store NOI growth. Positive sector read-through (see Peer Commentary section for detail).
• June 2, 2026 — American Healthcare REIT (AHR) at Nareit REITweek: bullish SHO demand/supply commentary; "very nice" NOI growth expected in 2026 and 2027. Positive sector read-through (see Peer Commentary section for detail).

8. Insider Transaction Activity

Key Takeaway: No open-market insider purchases or sales (Form 4 transaction codes P/S) were identified for WELL in the period from April 28, 2026 through July 26, 2026. The absence of insider selling at elevated price levels ($212–$252 range) is a mild positive signal — insiders are not taking profits despite the stock's ~18% post-earnings run. No 10b5-1 plan initiations were identified in the search window.

Context: The lack of insider selling is notable given the stock's significant appreciation since Q1 earnings. Welltower's executive compensation structure (RIDEA 6.0) eliminates cash compensation for executives and ties wealth creation to Welltower stock performance, which may reduce the propensity for discretionary open-market sales. The absence of any clustered buying or selling activity provides no directional signal ahead of the print.

Source: SEC Form 4 Filings Database (open-market transaction codes P/S; filing date window April 28 – July 26, 2026; ticker WELL).

Appendix: Key Data Sources & Citations